Evaluation of the effects of vitamin D on left ventricular function and function class of patients with heart failure

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138706121181N1

Enrollment

Registered

2011-10-05

Start date

2007-10-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure. Heart failure

Interventions

Intervention 1: Intervention group will receive 50000 IU vitamin D per week for 6 months. Intervention 2: Control group will receive exactly similar placebo (cellulose) capsules regarding shape, size

Treatment - Drugs

Placebo

Intervention group will receive 50000 IU vitamin D per week for 6 months.

Control group will receive exactly similar placebo (cellulose) capsules regarding shape, size and taste.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion: ambulatory New York Heart Association (NYHA) Functional Class = III; LV ejection fraction (LVEF) = 45%. Exclusion: hypercalcemia; nephrolithiasis; intake of supplements containing vitamin D or calcium; therapy with corticosteroids or anticonvulsants; serum creatinine concentration > 2mg/dl.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Left ventricular ejection fraction (LVEF). Timepoint: six months. Method of measurement: Echocardiography.;Changes in Left ventricular ejection fraction. Timepoint: 6 months. Method of measurement: echocardiography.	—

Secondary

Measure	Time frame
NYHA function class. Timepoint: six months. Method of measurement: clinical interview.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMansour Siavash

Isfahan University of Medical Sciences

siavash@med.mui.ac.ir+98 31 1222 0998

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026